Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia

PHASE4CompletedINTERVENTIONAL
Enrollment

862

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Asthma
Interventions
DRUG

Symbicort (Budesonide/Formoterol)

Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms

Trial Locations (35)

Unknown

Research Site, Guangzhou

Research Site, Zheng Ahou

Research Site, Wuhan

Research Site, Changsha

Research Site, Qingdao

Research Site, Shanghai

Research Site, Beijing

Research Site, Chengdu

Research Site, Fuzhou

Research Site, Hangzhou

Research Site, Nanjing

Research Site, Shenyang

Research Site, Zhengzhou

Research Site, Hyderabad

Research Site, Ahmedabad

Research Site, Bangalore

Research Site, Bengaluru

Research Site, Indore

Research Site, Mumbai

Research Site, Chennai

Research Site, Coimbatore

Research Site, Lucknow

Research Site, Noida

Research Site, Jakarta

Research Site, Surabaya

Research Site, Chiayi City

Research Site, Kaohsiung City

Research Site, Taichung

Research Site, Taipei

Research Site, Taoyuan

Research Site, Taoyuan District

Research Site, Bangkok

Research Site, Pathumwan

Research Site, Pathum Thani

Research Site, Nakhonratchasima

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY